Doctors have said they didn’t expect him to live to see this day. But Monday marks a milestone: Johnson, 46, is the first of hundreds of cancer patients to see his case against agrochemical giant Monsanto go to trial.
Since then, hundreds more non-Hodgkin’s lymphoma patients have made similar claims, Johnson’s attorney, Timothy Litzenburg, said. He now represents “more than 2,000 non-Hodgkin’s lymphoma sufferers who used Roundup extensively,” he said.
Johnson, a father of two in California’s Bay Area, applied Roundup weed killer 20 to 30 times per year while working as a pest manager for a county school system, his attorney said.
And there’s a lot riding on this case, which could set a legal precedent for thousands of cases to follow.
Report on Roundup ingredient in dispute
The big questions at stake are whether Roundup can cause cancer and, if so, whether Monsanto failed to warn consumers about the product’s cancer risk.
“For the herbicide glyphosate, there was limited evidence of carcinogenicity in humans for non-Hodgkin lymphoma,” the report states.
“The evidence in humans is from studies of exposures, mostly agricultural, in the USA, Canada, and Sweden published since 2001. In addition, there is convincing evidence that glyphosate also can cause cancer in laboratory animals.”
“More than 800 scientific studies, the U.S. EPA (Environmental Protection Agency), the National Institutes of Health and regulators around the world have concluded that glyphosate is safe for use and does not cause cancer,” Scott Partridge, Monsanto’s vice president of strategy, said in a statement.
“We have empathy for anyone suffering from cancer, but the scientific evidence clearly shows that glyphosate was not the cause. We look forward to presenting this evidence to the court.”
Monsanto spokeswoman Charla Lord said regulatory authorities help ensure Roundup is safe.
“The safety of each labeled use of a pesticide formulation must be evaluated and approved by regulatory authorities before it is authorized for sale,” she has said.
Many more cases to follow
Johnson’s case — and hundreds of similar cases against Monsanto — have been filed in various state courts, Litzenburg said. Many other cases have been filed in federal multidistrict litigation, or MDL.
MDL is a procedure similar to class-action, in that it consolidates pre-trial proceedings for the sake of efficiency. But unlike a class-action lawsuit, each case within an MDL gets its own trial — with its own outcome.
In other words, one MDL plaintiff might get a large settlement, while another plaintiff might get nothing.
It’s not clear when future state or MDL trials will begin. One advantage of filing in state court — as Johnson did — instead of through MDL is that state courts might produce an outcome faster.
And in Johnson’s case, time is critical.
“Mr. Johnson is angry and is the most safety-oriented person I know,” his attorney said. “Right now, he is the bravest dude in America. Whatever happens with the trial and his health, his sons get to know that.”
CNN’s Theresa Waldrop contributed to this report.
more recommended stories
How undoing Obamacare would reshape American health care
The Affordable Care Act does far.
Special counsel Robert Mueller’s team: FBI interview did not lead Michael Flynn to make false statements
The special counsel’s office has filed.
Donald Trump offers new alternative facts to explain his problems
Trump had ignored the clear conclusion.
GM says it has 2,700 jobs for workers slated to be laid off
Interested in General Motors? Add General.
Cohen on Trump: The man doesn't tell the truth
President Donald Trump’s former attorney Michael.
Border Patrol defends handling, medical care of 7-year-old girl who died in custody
Department of Homeland Security and Border.
Mystery Mueller mayhem at a Washington court
But this Friday, court officials went.
Facebook says photo access for up to 6.8 million users unintentionally shared; ‘We’re sorry this happened’
Facebook said on Friday a software.
Michael Flynn’s criticism of FBI interview slammed by special counsel
However, Mueller’s office said it would.
Trump picks Mick Mulvaney, director of the Office of Management and Budget as new acting White House chief of staff
President Donald Trump has tapped Mich.